422 related articles for article (PubMed ID: 12006518)
1. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor.
Haider K; Kornek GV; Kwasny W; Weinländer G; Valencak J; Lang F; Püribauer F; Kovats E; Depisch D; Scheithauer W
Breast Cancer Res Treat; 1999 Jun; 55(3):203-11. PubMed ID: 10517165
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
7. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Hejna M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger WC; Marosi L; Schneeweiss B; Greul R; Scheithauer W
Cancer; 2000 Aug; 89(3):516-22. PubMed ID: 10931450
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Alexopoulos A; Kouroussis C; Malamos N; Kakolyris S; Kalbakis K; Kosmas C; Mavroudis D; Agelaki S; Vlachonicolis J; Sarra E; Rigatos G; Georgoulias V
Ann Oncol; 2001 Jun; 12(6):793-8. PubMed ID: 11484954
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Fountzilas G; Nicolaides C; Bafaloukos D; Kalogera-Fountzila A; Kalofonos H; Samelis G; Aravantinos G; Pavlidis N
Cancer Invest; 2000; 18(6):503-9. PubMed ID: 10923097
[TBL] [Abstract][Full Text] [Related]
12. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
13. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Frasci G; Comella P; D'Aiuto G; Thomas R; Capasso I; Elmo M; Botti G; Cortino GR; Lapenta L; De Rosa V; Vallone P; Petrillo A; Comella G
Ann Oncol; 2000 Mar; 11(3):367-71. PubMed ID: 10811508
[TBL] [Abstract][Full Text] [Related]
14. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Georgoulias V; Kouroussis C; Androulakis N; Kakolyris S; Dimopoulos MA; Papadakis E; Bouros D; Apostolopoulou F; Papadimitriou C; Agelidou A; Hatzakis K; Kalbakis K; Kotsakis A; Vardakis N; Vlachonicolis J
J Clin Oncol; 1999 Mar; 17(3):914-20. PubMed ID: 10071284
[TBL] [Abstract][Full Text] [Related]
15. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Pagani O; Sessa C; Nolè F; Crivellari D; Lombardi D; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Zucchetti M; D'Incalci M; Goldhirsch A
Ann Oncol; 2000 Aug; 11(8):985-91. PubMed ID: 11038035
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Stathopoulos GP; Mavroudis D; Tsavaris N; Kouroussis C; Aravantinos G; Agelaki S; Kakolyris S; Rigatos SK; Karabekios S; Georgoulias V
Ann Oncol; 2001 Jan; 12(1):101-3. PubMed ID: 11249034
[TBL] [Abstract][Full Text] [Related]
18. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
[TBL] [Abstract][Full Text] [Related]
19. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
